Online citations, reference lists, and bibliographies.

Specific Splice Variants Are Associated With Parkinson's Disease.

José A. Santiago, C. Scherzer, J. Potashkin
Published 2013 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Diagnosis of Parkinson's disease (PD) currently relies on assessment of motor symptoms. Recently, sensitive, specific, and readily available splice variant-specific biomarkers were identified in peripheral blood from participants in the Diagnostic and Prognostic Biomarkers in Parkinson Disease study. METHODS Here we test for an association between candidate splice variant biomarkers and PD in blood of an independent population of cases and controls nested in the Harvard NeuroDiscovery Center Biomarker Study. RESULTS Expression of 7 out of 13 candidate biomarkers was dysregulated in whole cellular blood of patients with PD. CONCLUSIONS These results support the view that differential expression of a subset of splice-variant markers in blood is associated with PD. Further evaluation in untreated, de novo patients and at-risk subjects is warranted.
This paper references
10.1093/nar/gkq537
The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function
David Warde-Farley (2010)
10.1074/jbc.M111.247981
Endothelial Surface N-Glycans Mediate Monocyte Adhesion and Are Targets for Anti-inflammatory Effects of Peroxisome Proliferator-activated Receptor γ Ligands*
Balu K. Chacko (2011)
10.1186/1750-1326-7-26
A molecular signature in blood identifies early Parkinson’s disease
L. Molochnikov (2012)
10.1073/pnas.0610204104
Molecular markers of early Parkinson's disease based on gene expression in blood
C. Scherzer (2007)
10.1126/science.1227568
JNK Expression by Macrophages Promotes Obesity-Induced Insulin Resistance and Inflammation
M. S. Han (2013)
10.1126/scitranslmed.3001059
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
B. Zheng (2010)
10.1111/j.1460-9568.2009.06657.x
PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease
Nicoletta Schintu (2009)
10.1073/PNAS.0502143102
Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.
A. Jaeschke (2005)
10.1002/mds.23934
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.
H. Ding (2011)
10.1371/journal.pone.0043595
Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients
J. Potashkin (2012)
10.1016/j.molmed.2013.01.002
Shared dysregulated pathways lead to Parkinson's disease and diabetes.
José A. Santiago (2013)
10.1159/000332598
Exon Arrays Reveal Alternative Splicing Aberrations in Parkinson’s Disease Leukocytes
L. Soreq (2011)



This paper is referenced by
10.1007/s12035-018-1315-2
Upgraded Methodology for the Development of Early Diagnosis of Parkinson’s Disease Based on Searching Blood Markers in Patients and Experimental Models
A. Kim (2018)
10.1038/s41531-020-00127-w
Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease
Chang Su (2020)
10.3390/diagnostics4040153
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
José A. Santiago (2014)
10.3389/fnagi.2018.00157
Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
José A. Santiago (2018)
10.1038/srep34579
Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease
José A. Santiago (2016)
10.1038/srep37116
Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases
Rasmus Rydbirk (2016)
10.1016/j.nbd.2019.01.003
Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease
E. Glaab (2019)
10.3233/JPD-171155
Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.
José A. Santiago (2017)
10.1007/s10048-015-0449-x
Splicing: is there an alternative contribution to Parkinson’s disease?
Valentina La Cognata (2015)
10.1016/j.molmed.2014.10.002
A network approach to clinical intervention in neurodegenerative diseases.
José A. Santiago (2014)
10.1371/journal.pone.0142582
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients
José A. Santiago (2015)
10.1073/pnas.1423573112
Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease
José A. Santiago (2015)
10.1002/mds.25761
A network approach to diagnostic biomarkers in progressive supranuclear palsy.
José A. Santiago (2014)
10.1371/journal.pone.0109042
Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson's Disease
José A. Santiago (2014)
10.1007/s00441-017-2734-5
Computational systems biology approaches for Parkinson’s disease
E. Glaab (2017)
10.1073/pnas.1508415112
Reply to Toker and Pavlidis: Blood biomarkers for Parkinson’s disease
José A. Santiago (2015)
10.1371/journal.pone.0083940
Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes
José A. Santiago (2013)
Semantic Scholar Logo Some data provided by SemanticScholar